Article
Pharmacology & Pharmacy
Sara Vaccaro, Alessandra Rossetti, Antonella Porrazzo, Simona Camero, Matteo Cassandri, Silvia Pomella, Miriam Tomaciello, Giampiero Macioce, Francesca Pedini, Giovanni Barillari, Cinzia Marchese, Rossella Rota, Giovanni Cenci, Mario Tombolini, Robert A. Newman, Peiying Yang, Silvia Codenotti, Alessandro Fanzani, Francesca Megiorni, Claudio Festuccia, Giuseppe Minniti, Giovanni Luca Gravina, Francesca Vulcano, Luisa Milazzo, Francesco Marampon
Summary: The therapeutic properties of PBI-05204, an extract from Nerium oleander, were studied in the treatment of rhabdomyosarcoma (RMS). PBI-05204 inhibited the growth and invasion abilities of RMS and improved its sensitivity to radiotherapy. Additionally, PBI-05204 suppressed the formation of cancer stem cells in RMS.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Maoyuan Sun, Honglei Xie, Wenli Zhang, Xianlu Li, Zhan Jiang, Yiyu Liang, Guanjian Zhao, Ning Huang, Jinning Mao, Guodong Liu, Zhiwen Zhang
Summary: A bioinspired lipoprotein system based on CCL5 is designed to target GBM and overcome radiotherapy resistance by releasing gemcitabine and NO.
Article
Engineering, Biomedical
Qi Xu, Hao Zhang, Hanghang Liu, Yaobao Han, Weibao Qiu, Zhen Li
Summary: The study reveals a novel mechanism of core-shell copper selenide coated gold nanoparticles inhibiting the protective autophagy and DNA repair of tumor cells, significantly enhancing the radiotherapy efficacy of glioblastoma.
Article
Pharmacology & Pharmacy
Changyong Wu, Yang Shen, Lin Shi, Junhao Zhang, Tongxuan Guo, Lingni Zhou, Wanzhou Wang, Xu Zhang, Rutong Yu, Xuejiao Liu
Summary: Glioblastoma multiforme (GBM) is a highly deadly brain tumor. UBA1 inhibition by TAK-243 can increase the sensitivity of GBM to radiotherapy by impairing DNA double-strand break repair. This study provides a new therapeutic strategy for improving the radiation sensitivity of GBM and lays a foundation for further clinical trials.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Hong Shik Yun, Jennifer Lee, Whoon Jong Kil, Tamalee R. Kramp, Philip J. Tofilon, Kevin Camphausen
Summary: AZD0530, a potent small-molecule inhibitor of the Src kinase family, enhances the radiosensitivity of glioblastoma cells and glioblastoma stem-like cells, showing potential as a clinical radiosensitizer for the treatment of glioblastoma.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Zili Tang, Ivana Dokic, Maximilian Knoll, Federica Ciamarone, Christian Schwager, Carmen Klein, Gina Cebulla, Dirk C. Hoffmann, Julian Schlegel, Philipp Seidel, Christiane Rutenberg, Stephan Brons, Christel Herold-Mende, Wolfgang Wick, Juergen Debus, Dieter Lemke, Amir Abdollahi
Summary: This study reveals that invasive tumor cells in glioblastoma exhibit high radioresistance and are closely associated with patient prognosis. Transcriptome analysis identifies the gene expression profile of invasive cells and validates the involvement of key pathways. Inhibition of specific signaling pathways and the use of carbon ion therapy can enhance the sensitivity of invasive cells to radiation treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Bernd Kaina, Lea Beltzig, Herwig Strik
Summary: Radiation concomitant with the DNA methylating drug temozolomide (TMZ) is the gold standard in the treatment of glioblastoma. TMZ acts as a radiation sensitizer and also induces cell death and DNA damage. Giving TMZ before radiation treatment may enhance the cytotoxic effect.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Parvaneh Mahinfar, Behnaz Mansoori, Davoud Rostamzadeh, Behzad Baradaran, William C. Cho, Behzad Mansoori
Summary: This article highlights the roles of functional microRNAs in the diagnosis and treatment of drug-resistant GBM, suggesting effective treatment strategies based on the expression profiles of these miRNAs. Glioblastoma is an aggressive brain tumor with poor prognosis mainly due to drug resistance, and the review discusses the underlying mechanisms and potential new avenues for treatment.
Review
Oncology
Yanbei Kuang, Jian Kang, Hongbin Li, Bingtao Liu, Xueshan Zhao, Linying Li, Xiaodong Jin, Qiang Li
Summary: p21 plays a crucial role in regulating radiation responses by participating in multiple cellular processes. Further insights into the functions of p21 are needed to make it a safe and effective therapeutic target in cancer radiotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Phuoc T. Tran, Kathryn Lowe, Hua-Ling Tsai, Daniel Y. Song, Arthur Y. Hung, Jason W. D. Hearn, Steven Miller, James A. Proudfoot, Matthew P. Deek, Ryan Phillips, Tamara Lotan, Channing J. Paller, Catherine H. Marshall, Mark Markowski, Shirl Dipasquale, Samuel Denmeade, Michael Carducci, Mario Eisenberger, Theodore L. DeWeese, Matthew Orton, Curtiland Deville, Elai Davicioni, Stanley L. Liauw, Elisabeth I. Heath, Stephen Greco, Neil B. Desai, Daniel E. Spratt, Felix Feng, Hao Wang, Tomasz M. Beer, Emmanuel S. Antonarakis
Summary: This study aimed to investigate the effect of enzalutamide on freedom from PSA progression in men with recurrent prostate cancer after radical prostatectomy. The results showed that enzalutamide monotherapy for 6 months in combination with salvage radiation therapy delayed PSA progression and was safe for high-risk patients with postoperative recurrence.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Miguel Jimenez-Alcazar, Alvaro Curiel-Garcia, Paula Nogales, Javier Perales-Paton, Alberto J. Schuhmacher, Marcos Galan-Ganga, Lucia Zhu, Scott W. Lowe, Fatima Al-Shahrour, Massimo Squatrito
Summary: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, and chemotherapy resistance is a major challenge in its treatment. Research has identified mechanisms driving temozolomide (TMZ) resistance, and a potential treatment using Val-083 has shown promising results in bypassing these resistance mechanisms. Combination therapy with TMZ and Val-083 appears to be synergistic in targeting GBM cells, suggesting a potential new approach for patients with GBM.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Multidisciplinary Sciences
Jingming Ren, Rong Huang, Yanjie Li, Ruiyang Chen, Hongqi Tian, Chenlu Liu
Summary: This study demonstrates that HL-003 has a protective effect on radiation-induced salivary gland injury. HL-003 can prevent damage through multiple mechanisms, including preserving salivary secretion function, reducing oxidative stress, and inhibiting cell apoptosis.
SCIENTIFIC REPORTS
(2022)
Article
Cell Biology
Alessandro Tancredi, Olga Gusyatiner, Pierre Bady, Michelle C. Buri, Remy Lomazzi, Davide Chiesi, Mahmoud Messerer, Monika E. Hegi
Summary: Bromodomain and extra-terminal tail (BET) proteins are potential epigenetic targets in cancer, including glioblastoma. BET inhibitors disrupt the histone code-gene transcription link. BET-induced differential gene expression in glioblastoma derived-spheres revealed 6 distinct response patterns. The O-6-methylguanine-DNA methyltransferase (MGMT) gene, a known resistance factor for glioblastoma treatment, showed consistent downregulation in response to BET inhibitors.
CELL DEATH & DISEASE
(2022)
Review
Medicine, Research & Experimental
Sushmitha Sriramulu, Shivani Thoidingjam, Stephen L. Brown, Farzan Siddiqui, Benjamin Movsas, Shyam Nyati
Summary: Radiotherapy is a commonly used cytotoxic therapy for solid cancers, utilizing ionizing radiation to damage DNA and kill tumor cells. Radioresistance is often caused by dysregulated DNA damage repair processes. Radiosensitizers enhance radiation-mediated DNA damage and inhibit DNA repair, leading to accumulation of DNA damages, cell-cycle arrest, and cell death. New molecularly targeted radiosensitizing agents that target key signals in DNA damage response are being evaluated in studies to enhance radiation cytotoxicity and reduce normal tissue toxicity.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Neurosciences
Yun Dong, Yiping Xiong, Duanyang Zhou, Min Yao, Xiao Wang, Wenchuan Bi, Jian Zhang
Summary: TRIM56 expression is associated with poor prognosis in glioblastoma. TRIM56 reduces the radiosensitivity of glioblastoma cells by regulating FOXM1-mediated DNA repair.
MOLECULAR NEUROBIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Zixuan Wang, Stefano Martellucci, Alicia Van Enoo, Dana Austin, Cohava Gelber, Wendy M. Campana
Summary: SP16, derived from AAT, is a bioactive peptide that can increase neurite length and regenerative gene expression in sensory neurons. It activates the Akt and ERK1/2 cell-signaling pathways in an LRP1-dependent manner. SP16 shows efficacy in attenuating nociceptive, inflammatory, and neuropathic pain in three different pain models, and also inhibits inflammatory cell recruitment and satellite cell activation.
Article
Neurosciences
Mahrou Sadri, Naoya Hirosawa, Jasmine Le, Haylie Romero, Stefano Martellucci, Hyo Jun Kwon, Donald Pizzo, Seiji Ohtori, Steven L. Gonias, Wendy M. Campana
Summary: Schwann cells produce extracellular vesicles that can regulate the activity of TNF alpha through sequestering TNFR1, acting as a decoy and protecting the nervous system from potential toxic effects. SC EVs provide a novel mechanism for spatial and temporal regulation of neuro-inflammation.
Review
Neurosciences
Alessio Crestini, Francesca Santilli, Stefano Martellucci, Elena Carbone, Maurizio Sorice, Paola Piscopo, Vincenzo Mattei
Summary: Specific protein misfolding and aggregation are mechanisms underlying neurodegenerative diseases such as prion disease and Alzheimer's disease (AD). The misfolded proteins contribute to the pathological features of AD, including the formation of plaques and neurofibrillary tangles. The cellular prion protein (PrPC) has an important role in the pathogenesis of AD.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Antonella Capozzi, Daniela Caissutti, Vincenzo Mattei, Francesca Gado, Stefano Martellucci, Agostina Longo, Serena Recalchi, Valeria Manganelli, Gloria Riitano, Tina Garofalo, Maurizio Sorice, Clementina Manera, Roberta Misasi
Summary: This study evaluated the biological activity of a novel CBR2 agonist, JT11, and found that it has potential anti-inflammatory effects. Results showed that JT11 regulates cell viability and proliferation through a CBR2-dependent mechanism and reduces inflammation. These findings suggest that therapeutic strategies targeting CBR2 signaling may hold promise for the treatment of chronic inflammatory diseases.
Article
Cell Biology
Gloria Riitano, Antonella Capozzi, Serena Recalchi, Daniela Caissutti, Agostina Longo, Vincenzo Mattei, Fabrizio Conti, Roberta Misasi, Tina Garofalo, Maurizio Sorice, Valeria Manganelli
Summary: This study analyzed the induction of Tissue Factor (TF) expression in endothelial cells by anti-beta 2-GPI antibodies from patients with APS through a LRP6 signal transduction pathway involving lipid rafts. The results showed that the anti-beta 2-GPI antibodies triggered LRP6 phosphorylation and subsequent activation of beta-catenin, leading to TF expression on the cell surface.
Article
Biochemistry & Molecular Biology
Simona Delle Monache, Fanny Pulcini, Francesca Santilli, Stefano Martellucci, Costantino Santacroce, Jessica Fabrizi, Adriano Angelucci, Maurizio Sorice, Vincenzo Mattei
Summary: Studies suggest that hypoxia treatment of DPSCs promotes their differentiation into neuronal cells in a time-dependent manner. Additionally, the conditioned media from hypoxia-stimulated DPSCs can induce neural differentiation in other neural cells.
Article
Biochemistry & Molecular Biology
Annamaria Tisi, Fanny Pulcini, Giulia Carozza, Vincenzo Mattei, Vincenzo Flati, Maurizio Passacantando, Cinzia Antognelli, Rita Maccarone, Simona Delle Monache
Summary: The study demonstrates that cerium oxide nanoparticles can counteract retinal neovascularization induced by oxidative damage, suggesting a potential new therapeutic strategy for wet AMD treatment.
Article
Oncology
Andrea Mancini, Alessandro Colapietro, Loredana Cristiano, Alessandra Rossetti, Vincenzo Mattei, Giovanni Luca Gravina, Hector Perez-Montoyo, Marc Yeste-Velasco, Jose Alfon, Carles Domenech, Claudio Festuccia
Summary: ABTL0812, as a novel therapy for glioblastoma, has been demonstrated to inhibit cell proliferation, induce cell differentiation, and reduce invasion in GBM cell lines and GSCs. It exerts its anti-cancer efficacy by inhibiting the Akt/mTORC1 axis and activating the ER stress/UPR pathway, leading to autophagy-mediated cell death. In vivo studies have shown that ABTL0812 impairs tumor growth and increases disease-free survival in xenograft tumor models. Furthermore, it synergizes with radiotherapy and temozolomide, the standard of care treatments for GBM, to enhance their efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Sara Vaccaro, Alessandra Rossetti, Antonella Porrazzo, Simona Camero, Matteo Cassandri, Silvia Pomella, Miriam Tomaciello, Giampiero Macioce, Francesca Pedini, Giovanni Barillari, Cinzia Marchese, Rossella Rota, Giovanni Cenci, Mario Tombolini, Robert A. Newman, Peiying Yang, Silvia Codenotti, Alessandro Fanzani, Francesca Megiorni, Claudio Festuccia, Giuseppe Minniti, Giovanni Luca Gravina, Francesca Vulcano, Luisa Milazzo, Francesco Marampon
Summary: The therapeutic properties of PBI-05204, an extract from Nerium oleander, were studied in the treatment of rhabdomyosarcoma (RMS). PBI-05204 inhibited the growth and invasion abilities of RMS and improved its sensitivity to radiotherapy. Additionally, PBI-05204 suppressed the formation of cancer stem cells in RMS.
FRONTIERS IN PHARMACOLOGY
(2022)
Editorial Material
Biochemistry & Molecular Biology
Vincenzo Mattei, Simona Delle Monache
Review
Biochemistry & Molecular Biology
Francesca Santilli, Jessica Fabrizi, Fanny Pulcini, Costantino Santacroce, Maurizio Sorice, Simona Delle Monache, Vincenzo Mattei
Summary: This review critically analyzes the role of gangliosides in the differentiation of mesenchymal stem cells and examines their potential use as specific cell surface markers.
Review
Cell Biology
Niccolo Candelise, Francesca Santilli, Jessica Fabrizi, Daniela Caissutti, Zaira Spinello, Camilla Moliterni, Loreto Lancia, Simona Delle Monache, Vincenzo Mattei, Roberta Misasi
Summary: Despite the lack of available therapies for neurodegenerative disorders, cell therapy using stem cells from various sources, such as dental pulp stem cells, has shown promise in preclinical models. These stem cells can be reprogrammed for neural differentiation and have potential applications in the treatment of nervous system disorders. This review summarizes the advancements and differences in the maintenance, differentiation, and potential clinical application of such stem cells.
Article
Cell Biology
Valeria Manganelli, Roberta Misasi, Gloria Riitano, Antonella Capozzi, Vincenzo Mattei, Tuba Rana Caglar, Davide Ialongo, Valentina Noemi Madia, Antonella Messore, Roberta Costi, Roberto Di Santo, Maurizio Sorice, Tina Garofalo
Summary: This research investigated a new HPSE inhibitor, RDS 3337, and its role in regulating the autophagic process and the balance between apoptosis and autophagy in U87 glioblastoma cells. The results showed that RDS 3337 inhibited autophagic-lysosomal flux, leading to the accumulation of lipidated LC3-II form. This inhibition of autophagic flux activated apoptosis mechanisms. These findings suggest a potential role for HPSE inhibitors in controlling tumor growth progression by balancing apoptosis and autophagy.
Editorial Material
Biochemistry & Molecular Biology
Vincenzo Mattei, Simona Delle Monache